Dengue - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 204 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dengue - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Dengue - Pipeline Review, H2 2015', provides an overview of the Dengue's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dengue and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dengue

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dengue
 and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dengue
 products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dengue
 pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dengue

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dengue
 pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dengue Overview 9
Therapeutics Development 10
Pipeline Products for Dengue - Overview 10
Pipeline Products for Dengue - Comparative Analysis 11
Dengue - Therapeutics under Development by Companies 12
Dengue - Therapeutics under Investigation by Universities/Institutes 17
Dengue - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Dengue - Products under Development by Companies 22
Dengue - Products under Investigation by Universities/Institutes 26
Dengue - Companies Involved in Therapeutics Development 28
Abivax S.A. 28
Agilvax, Inc. 29
AltraVax Inc. 30
Arbovax, Inc. 31
BCI Pharma 32
BioDiem Ltd 33
Bioneer Corporation 34
Biotron Limited 35
CalAsia Pharmaceuticals, Inc. 36
Canopus BioPharma Incorporated 37
Cocrystal Pharma, Inc. 38
Codagenix, Inc. 39
GlaxoSmithKline Plc 40
Humabs BioMed SA 41
Immunotope, Inc. 42
Immunovaccine, Inc. 43
Inovio Pharmaceuticals, Inc. 44
Johnson & Johnson 45
Kineta, Inc. 46
Merck & Co., Inc. 47
Molplex Ltd. 48
Myelo Therapeutics GmbH 49
NanoViricides, Inc. 50
Panacea Biotec Limited 51
PaxVax 52
Prosetta Antiviral Inc. 53
Sanofi Pasteur SA 54
Sarepta Therapeutics, Inc. 55
SIGA Technologies, Inc. 56
SKAU Vaccines ApS 57
Takeda Pharmaceutical Company Limited 58
TechnoVax, Inc. 59
Tekmira Pharmaceuticals Corp. 60
Themis Bioscience GmbH 61
United Therapeutics Corporation 62
VaxInnate Corporation 63
Visterra, Inc. 64
Dengue - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Target 66
Assessment by Mechanism of Action 68
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
ABX-220 - Drug Profile 74
Antisense RNAi Oligonucleotide for Dengue - Drug Profile 75
BG-323 - Drug Profile 76
CB-010 - Drug Profile 77
celgosivir hydrochloride - Drug Profile 78
dengue (serotype DEN-2) vaccine - Drug Profile 79
dengue (tetravalent) vaccine - Drug Profile 80
dengue (tetravalent) vaccine - Drug Profile 81
dengue (tetravalent) vaccine - Drug Profile 83
dengue (tetravalent) vaccine - Drug Profile 84
dengue (tetravalent) vaccine - Drug Profile 85
dengue (tetravalent) vaccine - Drug Profile 86
dengue (tetravalent) vaccine - Drug Profile 87
dengue (tetravalent) vaccine - Drug Profile 88
dengue (tetravalent) vaccine - Drug Profile 89
dengue (tetravalent) vaccine 3 - Drug Profile 90
dengue (tetravalent) vaccine 4 - Drug Profile 92
dengue (tetravalent) vaccines - Drug Profile 93
dengue [rDEN1delta30, rDEN2/4delta30(ME), rDEN3delta30/31 and rDEN4delta30] (tetravalent) vaccine - Drug Profile 94
dengue [serotype 2] vaccine - Drug Profile 95
dengue [serotype DEN-1, DEN-2] vaccine - Drug Profile 96
dengue [serotype DEN-1] vaccine - Drug Profile 97
dengue [serotype DENV-2] vaccine - Drug Profile 98
dengue [serotypes 1,2,3,4] (tetravalent) vaccine - Drug Profile 99
dengue [serotypes 1,2,3,4] (tetravalent) vaccine - Drug Profile 102
dengue [serotypes 1,2,3,4] (tetravalent) vaccine - Drug Profile 103
dengue [serotypes 1,3,4] (trivalent) vaccine - Drug Profile 104
dengue fever vaccine - Drug Profile 105
dengue vaccine - Drug Profile 106
dengue vaccine - Drug Profile 107
dengue vaccine - Drug Profile 108
dengue vaccine - Drug Profile 109
dengue vaccine 4 - Drug Profile 110
dengue virus like particle vaccine - Drug Profile 111
DengueCide - Drug Profile 112
DiTU - Drug Profile 113
DV-2DeltaGVII - Drug Profile 114
DV-2DeltaLIG - Drug Profile 115
DV-2G460P - Drug Profile 116
ETX-101 - Drug Profile 117
FDX-000 - Drug Profile 118
fenretinide - Drug Profile 119
FX-06 - Drug Profile 120
GBV-001 - Drug Profile 122
GBV-006 - Drug Profile 123
GREDEN/V1-4 - Drug Profile 124
LCTA-949 - Drug Profile 125
LVM-142 - Drug Profile 126
modipafant - Drug Profile 127
Monoclonal Antibodies to Inhibit Virion, prM and E Proteins for Dengue - Drug Profile 128
Monoclonal Antibody for Dengue - Drug Profile 129
Monoclonal Antibody for Dengue - Drug Profile 130
Myelo-001 - Drug Profile 131
PAV-866 - Drug Profile 132
PY-2 - Drug Profile 133
Recombinant Peptide to Inhibit Dengue Protease for Dengue - Drug Profile 134
rOAS - Drug Profile 135
RS-1137 - Drug Profile 136
RS-1142 - Drug Profile 137
RS-1145 - Drug Profile 138
RS-930 - Drug Profile 139
RS-961 - Drug Profile 140
Small Molecule for Dengue - Drug Profile 141
Small Molecule for Dengue - Drug Profile 142
Small Molecule for Dengue - Drug Profile 143
Small Molecule to Agonize IRF-3 for Viral Infections - Drug Profile 144
Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection - Drug Profile 145
Small Molecule to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 146
Small Molecule to Inhibit NS5 for Dengue and Flavivirus Infections - Drug Profile 147
Small Molecules for Dengue - Drug Profile 148
Small Molecules for Dengue - Drug Profile 149
Small Molecules Inhibiting M Protein for Dengue - Drug Profile 150
Small Molecules to Activate AMPK for Dengue - Drug Profile 151
Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile 152
Small Molecules to Inhibit Furin for Dengue - Drug Profile 154
Small Molecules to Inhibit NS4B for Dengue - Drug Profile 155
Small Molecules to Inhibit Pan Polymerase for Dengue - Drug Profile 156
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections - Drug Profile 157
Small Molecules to Inhibit Serine Protease for Viral Infections - Drug Profile 158
ST-148 - Drug Profile 159
ST-324 - Drug Profile 161
ST-610 - Drug Profile 162
Synthetic Peptide for West Nile Virus and Dengue Virus Infections - Drug Profile 163
TAK-003 - Drug Profile 164
TDEN-PIV - Drug Profile 166
TVX-005 - Drug Profile 167
UV-4B - Drug Profile 168
V-180 - Drug Profile 169
Viral PMO-X - Drug Profile 171
VIS-513 - Drug Profile 172
Dengue - Recent Pipeline Updates 173
Dengue - Dormant Projects 179
Dengue - Discontinued Products 183
Dengue - Product Development Milestones 184
Featured News & Press Releases 184
Appendix 196
Methodology 196
Coverage 196
Secondary Research 196
Primary Research 196
Expert Panel Validation 196
Contact Us 196
Disclaimer 197

List of Tables

Number of Products under Development for Dengue, H2 2015 17
Number of Products under Development for Dengue - Comparative Analysis, H2 2015 18
Number of Products under Development by Companies, H2 2015 20
Number of Products under Development by Companies, H2 2015 (Contd..1) 21
Number of Products under Development by Companies, H2 2015 (Contd..2) 22
Number of Products under Development by Companies, H2 2015 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2015 25
Comparative Analysis by Late Stage Development, H2 2015 26
Comparative Analysis by Clinical Stage Development, H2 2015 27
Comparative Analysis by Early Stage Development, H2 2015 28
Products under Development by Companies, H2 2015 29
Products under Development by Companies, H2 2015 (Contd..1) 30
Products under Development by Companies, H2 2015 (Contd..2) 31
Products under Development by Companies, H2 2015 (Contd..3) 32
Products under Investigation by Universities/Institutes, H2 2015 33
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 34
Dengue - Pipeline by Abivax S.A., H2 2015 35
Dengue - Pipeline by Agilvax, Inc., H2 2015 36
Dengue - Pipeline by AltraVax Inc., H2 2015 37
Dengue - Pipeline by Arbovax, Inc., H2 2015 38
Dengue - Pipeline by BCI Pharma, H2 2015 39
Dengue - Pipeline by BioDiem Ltd, H2 2015 40
Dengue - Pipeline by Bioneer Corporation, H2 2015 41
Dengue - Pipeline by Biotron Limited, H2 2015 42
Dengue - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2015 43
Dengue - Pipeline by Canopus BioPharma Incorporated, H2 2015 44
Dengue - Pipeline by Cocrystal Pharma, Inc., H2 2015 45
Dengue - Pipeline by Codagenix, Inc., H2 2015 46
Dengue - Pipeline by GlaxoSmithKline Plc, H2 2015 47
Dengue - Pipeline by Humabs BioMed SA, H2 2015 48
Dengue - Pipeline by Immunotope, Inc., H2 2015 49
Dengue - Pipeline by Immunovaccine, Inc., H2 2015 50
Dengue - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 51
Dengue - Pipeline by Johnson & Johnson, H2 2015 52
Dengue - Pipeline by Kineta, Inc., H2 2015 53
Dengue - Pipeline by Merck & Co., Inc., H2 2015 54
Dengue - Pipeline by Molplex Ltd., H2 2015 55
Dengue - Pipeline by Myelo Therapeutics GmbH, H2 2015 56
Dengue - Pipeline by NanoViricides, Inc., H2 2015 57
Dengue - Pipeline by Panacea Biotec Limited, H2 2015 58
Dengue - Pipeline by PaxVax, H2 2015 59
Dengue - Pipeline by Prosetta Antiviral Inc., H2 2015 60
Dengue - Pipeline by Sanofi Pasteur SA, H2 2015 61
Dengue - Pipeline by Sarepta Therapeutics, Inc., H2 2015 62
Dengue - Pipeline by SIGA Technologies, Inc., H2 2015 63
Dengue - Pipeline by SKAU Vaccines ApS, H2 2015 64
Dengue - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 65
Dengue - Pipeline by TechnoVax, Inc., H2 2015 66
Dengue - Pipeline by Tekmira Pharmaceuticals Corp., H2 2015 67
Dengue - Pipeline by Themis Bioscience GmbH, H2 2015 68
Dengue - Pipeline by United Therapeutics Corporation, H2 2015 69
Dengue - Pipeline by VaxInnate Corporation, H2 2015 70
Dengue - Pipeline by Visterra, Inc., H2 2015 71
Assessment by Monotherapy Products, H2 2015 72
Number of Products by Stage and Target, H2 2015 74
Number of Products by Stage and Mechanism of Action, H2 2015 76
Number of Products by Stage and Route of Administration, H2 2015 78
Number of Products by Stage and Molecule Type, H2 2015 80
Dengue Therapeutics - Recent Pipeline Updates, H2 2015 180
Dengue - Dormant Projects, H2 2015 186
Dengue - Dormant Projects (Contd..1), H2 2015 187
Dengue - Dormant Projects (Contd..2), H2 2015 188
Dengue - Dormant Projects (Contd..3), H2 2015 189
Dengue - Discontinued Products, H2 2015 190